Advertisement
Advertisement
ARTL
Artelo Biosciences, Inc. Common Stock
1.91
USDSponsored
-0.21
-9.69%
Nov 06, 15:59 UTC -5
Closed
After-Market
1.95
+0.04
+1.83%
Artelo Biosciences, Inc. Common Stock (ARTL) Earnings
ARTL Earnings Reports
Positive Surprise Ratio
ARTL beat 8 of 16 last estimates.
50%
Next Report
Next Week
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Artelo Biosciences, Inc. Common Stock earnings per share and revenue
On Aug 12, 2026, ARTL reported earnings of -0.89 USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +3.51% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
INmune Bio Inc. Common stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.17
Surprise
-13.64%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
FAQ
What were Artelo Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Artelo Biosciences, Inc. Common Stock reported EPS of -$0.89, missing estimates by --, and revenue of $0.00, -- -- expectations.
How did the market react to Artelo Biosciences, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 3.51%, changed from $0.73 before the earnings release to $0.76 the day after.
When is Artelo Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Artelo Biosciences, Inc. Common Stock's next earnings report?
Based on --
analysts, Artelo Biosciences, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.